1. Home
  2. FC vs ALXO Comparison

FC vs ALXO Comparison

Compare FC & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Covey Company

FC

Franklin Covey Company

HOLD

Current Price

$21.13

Market Cap

231.6M

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$1.92

Market Cap

205.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FC
ALXO
Founded
1983
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
231.6M
205.9M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
FC
ALXO
Price
$21.13
$1.92
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$26.00
$3.50
AVG Volume (30 Days)
107.0K
882.8K
Earning Date
04-01-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.36
EPS
N/A
N/A
Revenue
$267,067,000.00
N/A
Revenue This Year
$3.15
N/A
Revenue Next Year
$4.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.16
$0.51
52 Week High
$26.81
$2.66

Technical Indicators

Market Signals
Indicator
FC
ALXO
Relative Strength Index (RSI) 52.04 47.02
Support Level $20.36 $1.42
Resistance Level $24.13 $2.31
Average True Range (ATR) 0.97 0.15
MACD 0.20 -0.02
Stochastic Oscillator 89.19 10.91

Price Performance

Historical Comparison
FC
ALXO

About FC Franklin Covey Company

Franklin Covey Co is a company focused on organizational performance improvement. It operates in the business segments of North America, International Direct Offices, International Licensees, Education Division. The company derives revenue from providing training and consulting services and through the sale of books, audio media, and other related products. It has a business presence in Australia, New Zealand, China, Japan, the United Kingdom, Ireland, and Other countries.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: